News
ETHZW
0.0090
-71.97%
-0.0231
Crypto Currents: Morgan Stanley’s bitcoin ETF debut meets ceasefire rally
TipRanks · 21h ago
Forum Markets Targets AI Chip Bridge Loan Opportunities
TipRanks · 1d ago
FORUM MARKETS, INC - HAS OPTION TO FUND ADDITIONAL AI CHIP INFRASTRUCTURE DEALS
Reuters · 1d ago
Forum Markets invests $25 million-$50 million in Nvidia GPU bridge loans targeting mid-teens returns
Reuters · 1d ago
Forum Markets enters AI chip bridge loan deal, targets mid-teens returns
Reuters · 1d ago
Forum to Participate in AI Chip Infrastructure Financing to Purchase NVIDIA GPUs; Targets Returns in the Mid-Teens
PR Newswire · 1d ago
Forum Markets Updates At-The-Market Sales Agreement Structure
TipRanks · 1d ago
Benchmark initiates Forum Markets coverage with Speculative Buy, USD 5 price target
Reuters · 1d ago
Forum Announces Initiation of Analyst Coverage by Benchmark
PR Newswire · 1d ago
Forum Markets Price Target Announced at $5.00/Share by Benchmark
Dow Jones · 2d ago
Forum Markets initiated with a Speculative Buy at Benchmark
TipRanks · 2d ago
FORUM MARKETS, INC <FRMM.O>: BENCHMARK INITIATES COVERAGE WITH SPECULATIVE BUY RATING; TARGET PRICE $5
Reuters · 2d ago
U.S. RESEARCH ROUNDUP-Centerspace, Union Pacific, XPO
Reuters · 2d ago
Forum Markets director Angela Dalton files initial beneficial ownership statement
Reuters · 2d ago
Weekly Report: what happened at FRMM last week (0330-0403)?
Weekly Report · 3d ago
Forum Markets Approves Equity Awards for Top Executives
TipRanks · 5d ago
Forum Markets grants CEO $4.3 million initial equity award under incentive plan
Reuters · 5d ago
Forum Markets Delays Annual 10-K Yearly Filing
TipRanks · 04/01 15:43
Forum Markets delays annual report filing, targets April 1 submission
Reuters · 04/01 10:06
Forum Markets FY25 net loss widens to $451 million; revenue rises to $6.5 million
Reuters · 03/31 20:10
More
Webull provides a variety of real-time ETHZW stock news. You can receive the latest news about ETHZilla Corporation through multiple platforms. This information may help you make smarter investment decisions.
About ETHZW
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.